VHL antibody (AA 101-213)

Catalog No. ABIN685537

This Rabbit Polyclonal antibody specifically detects VHL in ELISA, FACS, IF (cc), IF (p), IHC (p) and IHC (fro). It exhibits reactivity toward Human.

Quick Overview for VHL antibody (AA 101-213) (ABIN685537)

Target: VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This VHL antibody is un-conjugated

Application: ELISA, Flow Cytometry (FACS), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunohistochemistry (Frozen Sections) (IHC (fro))

Product Details anti-VHL Antibody

Binding Specificity: AA 101-213

Cross-Reactivity: Human

Predicted Reactivity: Mouse,Rat,Dog,Cow

Purification: Purified by Protein A.

Immunogen: KLH conjugated synthetic peptide derived from human VHL

Isotype: IgG

Application Details

Application Notes: ELISA 1:500-1000
FCM 1:20-100
IHC-P 1:200-400
IHC-F 1:100-500
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 μg/μL

Buffer: 0.01M TBS( pH 7.4) with 1 % BSA, 0.02 % Proclin300 and 50 % Glycerol.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Shipped at 4°C. Store at -20°C for one year. Avoid repeated freeze/thaw cycles.

Expiry Date: 12 months

Target Details for VHL

Target: VHL (Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase (VHL))

Alternative Name: VHL/HRCA1

Background:

Synonyms: Von Hippel Lindau, von Hippel-Lindau syndrome protein homolog, Hippel-Lindau disease tumor suppressor VHL, von Hippel-Lindau tumor suppressor isoform 1, VHL, HRCA1, RCA1, VHL1, von Hippel-Lindau disease tumor suppressor isoform 2,pVHL, pVHL, G7 protein, Elongin binding protein, Protein G7, VHL 1, VHL_HUMAN,VHL1, VHLH, Von Hippel Lindau disease tumor suppressor, von Hippel Lindau syndrome, von Hippel Lindau tumor suppressor, Von Hippel-Lindau disease tumor suppressor.

Background: Von Hippel-Lindau syndrome (VHL) is a dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors. A germline mutation of this gene is the basis of familial inheritance of VHL syndrome. The protein encoded by this gene is a component of the protein complex that includes elongin B, elongin C, and cullin-2, and possesses ubiquitin ligase E3 activity. This protein is involved in the ubiquitination and degradation of hypoxia-inducible-factor (HIF), which is a transcription factor that plays a central role in the regulation of gene expression by oxygen. RNA polymerase II subunit POLR2G/RPB7 is also reported to be a target of this protein. Alternatively spliced transcript variants encoding distinct isoforms have been observed. [provided by RefSeq].

Gene ID: 7428

Pathways: Tube Formation, Signaling Events mediated by VEGFR1 and VEGFR2, Ubiquitin Proteasome Pathway